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A B S T R A C T
Background: Long QT and use of QT-prolonging drugs are common among older patients receiving poly-
therapies, but real-world evidence on their impact in clinical practice is controversial. We investigated pre-
valence, variables associated and clinical implications of prolonged corrected QT (QTc) among patients from the
Syncope and Dementia study.
Methods: Observational, prospective, multicenter study. Patients≥65 years with dementia and fall suspected for
syncope in the previous three months were enrolled. Several clinical variables and the complete list of medi-
cations were recorded for each patient. A 12‑lead ECG was obtained and corrected QT was calculated by the
Bazett's formula. One-year followup for death and recurrent syncope was performed.
Results: Prolonged QTc was observed in 25% of the 432 enrolled patients (mean age 83.3), and was significantly
associated with male gender (OR 2.09; 95% CI 1.34–3.26) and diuretics use (OR 1.85; 95% CI 1.18–2.90). At
one-year 23.3% of patients died and 30.4% reported at least one recurrent event. Variables associated with one-
year mortality were: age, male gender, atrial fibrillation (AF), use of calcium channel blockers and prolonged
QTc (OR 1.80; 95% CI 1.01–3.20). Among patients with prolonged QTc a significant interaction for mortality
was found with AF. Recurrent events were associated with the use of antiplatelets, cholinesterase.
inhibitors and antipsychotics, but not with prolonged QTc.
Conclusions: We documented a high prevalence of prolonged QTc, that was associated with male gender and
diuretics but not with psychoactive medications. Patients with prolonged QTc had higher one-year mortality,
that was four-fold increased in those with concomitant AF.
1. Introduction
Long QT syndrome is an electro-physiologic disorder in which the
ventricular repolarization is lengthened, with an increased
susceptibility to ventricular tachy-arrhythmias, potentially leading to
syncope, cardiac arrest and sudden cardiac death [1]. Acquired pro-
longed QT interval is the most common form of long QT syndrome, and
usually results from the complex interplay between several factors
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including electrolyte imbalance, cardiac ischemia and structural heart
disease and drugs [1,2].
Older age by itself is a risk factor for QT prolongation [3–7];
moreover age-associated conditions such as presence of dementia and
polypharmacy make elderly patients at increased exposure to QT
prolonging drugs and consequently at risk of adverse associated out-
comes [8,9]. However, to the best of our knowledge, there are limited
data about prevalence and prognostic implications of prolonged QT in
real-world older patients.
The “Syncope and Dementia” study (SYD) was designed by the
Italian Group for the study of Syncope with the endorsement of the
Italian Geriatric Society in order to evaluate older patients with de-
mentia and suspected syncope or unexplained falls [10]. Advanced age,
the presence of dementia and the use of multiple medications, including
antipsychotics and antidepressants, make these patients a potentially
interesting target to investigate prevalence and clinical implications of
prolonged QTc (corrected QT).
Accordingly, the aims of the present study were: i) to investigate
prevalence and variables associated with prolonged QTc in older pa-
tients with dementia, and ii) to evaluate whether prolonged QTc was
associated with death and recurrence of syncope and falls at one-year.
2. Methods
This is a secondary analysis of the SYD [10] dataset, that was a
prospective observational study involving nine Italian departments of
Geriatrics. The overall study population consisted of 522 in- and out-
patients aged≥65 years referring to acute care wards, syncope units or
Alzheimer's evaluation units. The full study design, including the
standardized multidimensional geriatric assessment and the diagnostic
protocol applied for the diagnosis and management of syncope, has
been described elsewhere [10,11]. Briefly, consecutive patients with a
diagnosis of dementia, according to the Diagnostic and Statistical
Manual of Mental Disorders IV [12], and at least one episode of sus-
pected syncope or unexplained fall during the previous three months,
were enrolled. Informed consent was obtained from each patient. The
study protocol was approved by the Ethic Committee of the University
of Naples and then by each local ethical committee.
At their first visit patients underwent a full diagnostic evaluation,
including a 12‑leads-ECG, which was tape-recorded for further revision.
The QT interval was measured from the onset of QRS complex to the
end of the T wave (the intersection between the T wave tangent, drawn
at its maximum down slope, and the isoelectric line), and corrected for
the previous cardiac cycle length according to the Bazett's formula [13].
An averaged QT measure over 3 to 5 beats in a single lead was calcu-
lated both in patients with sinus rhythm and in those presenting with
atrial fibrillation (AF) [14] preferably using either lead II or lead V5. All
measurements where revised by an experienced cardiologist (MB). Pa-
tients with pace-maker and subjects without valid QTc measurements
were excluded from this analysis. Prolonged QTc was defined using a
threshold value of 450 milliseconds (ms) in males and 460ms in fe-
males [15].
The presence of comorbidities was investigated and their number
and severity were scored according to the Cumulative Illness Rating
Scale (CIRS) [16,17]. A complete list of pharmacological treatment,
coded according to the Anatomical Therapeutic and Chemical codes
[18] was collected for each patient; particular attention was given to
medications potentially prolonging QTc interval, including anti-
psychotics and antidepressants [19].
One year follow-up was conducted through planned visit or phone
interviews with patients' main caregiver, aiming to ascertain vital status
and recurrence of syncope or unexplained falls. For patients reporting
recurrent clinical events, medical documentation was obtained in order
to confirm the diagnosis.
Mean and standard deviation (SD) for continuous variables and
percentage for dichotomous variables were calculated. Variables
associated with prolonged QTc were evaluated at univariate analysis
using the χ2 test for categorical variables and the ANOVA for con-
tinuous variables. Significant variables at univariate analysis were then
introduced in a logistic regression model in order to identify those in-
dependently associated with prolonged QTc.
Variables associated with clinical outcomes (death and recurrent
syncope or unexplained fall), including the presence of prolonged QTc,
were identified at univariate analysis using the χ2 test for dichotomous
variables and ANOVA for continuous variables. Variables that achieved
the level of significance at univariate analysis where then introduced in
a stepwise multiple logistic model, in order to identify those in-
dependently associated with mortality and recurrent events at one year
(multivariate analysis, model 1). To test potential interactions with
prolonged QTc, variables significantly associated with mortality among
patients with prolonged QTc were identified, and then introduced in a
second multivariate analysis together with significant variables eval-
uated in the first model (multivariate analysis, model 2).
All statistical analysis were performed using the Software SPSS/
PC+. Statistical significance was set at p≤ .05.
3. Results
From February 2012 to October 2016, a total of 522 patients were
enrolled in the SYD study. Subjects without valid QTc measurements
were excluded, leaving a sample of 432 patients available for this study.
Main demographic and clinical characteristics of the overall sample of
patients and in those with and without prolonged QTc are reported in
Table 1. In the overall sample, mean age was 83.3 ± 6.2 years and
38.7% were males, with high prevalence of comorbidities and poor
level of basic and instrumental functional autonomy (Activities of Daily
Living scale (ADL) and Instrumental Activities of Daily Living scale
(IADL). The mean number of daily taken drugs was of 5.98 ± 2.81;
psychoactive medications were widely used, including antipsychotics
(24.5%), antidepressants (33.8%) and benzodiazepines (21.3%). The
average heart rate was 74.4 ± 15.1, and AF was present in 14.4% of
patients. The mean QTc length was 436.1 ± 26.6 ms and prolonged
QTc was observed in 25% of patients.
At univariate analysis, prolonged QTc was associated with male
gender (p= .001), use of diuretics (p= .008) and insulin (p= .024),
orthostatic hypotension (p= .006), AF (p= .037), heart rate
(p < .0001) and CIRS Severity Index (p= .01) (Table 1). After step-
wise multiple linear regression analysis, only male gender (Odds Ratio
(OR) 2.09, 95% CI 1.34–3.26) and diuretic use (OR 1.85, 95% CI
1.18–2.9) were significantly associated with a prolonged QTc.
Complete follow-up data at one year were not available for 77 pa-
tients, who were excluded from further analysis. Among the 355 re-
maining patients, 83 patients (23.3%) died (35.6% among patients with
prolonged QTc and 19.3% among patients with normal QTc), while
recurrence of syncope or unexplained fall was observed in 108 patients
(30.4%). Variables associated with one-year mortality and recurrence
of syncope or unexplained fall are reported in Table 2. After stepwise
multiple logistic model analysis (model 1) prolonged QTc was sig-
nificantly associated with all-cause mortality at one-year (OR 1.80; 95%
CI 1.01–3.20), along with age, male gender, AF and use of calcium
channel blockers (Table 3).
Among patients with prolonged QTc, several variables were sig-
nificantly associated with one-year mortality: male gender (OR 3.97;
95% IC 2.10–7.52), congestive heart failure (OR 5.24; 95% IC
1.44–19.04), AF (OR 6.42; 95% IC 2.44–16.91), anticoagulants (OR
3.47; 95% IC 1.07–11.17), age (OR 1.01; 95% IC 1.00–1.18), ADL score
(OR 1.22; 95% IC 1.08–1.38), CIRS Severity Index (OR 1.64; 95% IC
1.21–2.22) and CIRS Comorbidity Index (OR 1.22; 95% IC 1.08–1.39).
After introducing significant variables in the stepwise multiple logistic
model analysis (model 2) only the interaction between the presence of
AF and prolonged QTc was found to be significantly associated with
death, along with male gender, age and use of calcium channel blockers
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(Table 3).
No association was observed between prolonged QTc and recur-
rence of syncope or unexplained fall, which were significantly asso-
ciated with the use of antiplatelets (OR 1.72; 95% CI 1.07–2.76), cho-
linesterase inhibitors (OR 1.86; 95% CI 1.01–3.44) and antipsychotics
(OR 1.84; 95% CI 1.11–3.07).
4. Discussion
In a sample of older patients admitted for syncope or unexplained
falls we observed these main clinical findings: i) a high prevalence of
prolonged QTc interval, with one fourth of patients affected; ii) a sig-
nificant association of prolonged QTc with male gender and diuretic
use, but not with other specific drug-classes, including antipsychotics;
iii) prolonged QTc (along with male gender, increasing age, use of
calcium channel blockers and AF) was associated with higher one-year
mortality, with a four-fold increased risk in patients with concomitant
AF.
The prevalence of prolonged QTc observed in our sample is in
keeping with previous studies. Among 537 medical inpatients (70%
aged over 65 years), Pasquier et al. observed a prevalence of prolonged
QT of 22.3% [20], whereas Maison and colleagues reported a pre-
valence of 22% in a sample of older hospitalized patients, with a mean
age of 87 years [21].
With respect to determinants of prolonged QTc, several factors have
been reported in literature [22,23], including advancing age, female
gender and drug therapies. Although QT interval is usually longer in
adult women than in men until the sixth decade [5,24], only few studies
have investigated QT length in older patients [23]. In our sample of
elderly patients, we observed an association between male sex and
prolonged QTc (OR 2.09, 95% CI 1.34–3.26). Our findings are in
keeping with the study of Maison et al., that reported an increased
prevalence of prolonged QT in older males (OR 3.25, 95%CI 1.43–7.41)
[21]. Age-associated modifications of sex-steroid hormones might affect
cardiac repolarization; several studies have reported that lower levels of
testosterone were associated with longer QTc interval. [25–27].
In a sample of older patients with high prevalence of polypharmacy
and wide use of several drugs with potential QT prolonging effect, only
diuretics were significantly associated with prolonged QTc. More than
one-third of study patients were treated with diuretics, mainly thiazides
and furosemide. This association could be explained by diuretics effects
on potassium homeostasis [3,7,28,29], even if a causal relationship is
Table 1








Age, years, mean ± SD 83.3 ± 6.2 83.7 ± 6.2 83.1 ± 6.2 0.39
Heart rate, mean ± SD 74.4 ± 15.1 79.6 ± 15.0 72.7 ± 5.1 0.00003
MMSE score, mean ± SD 16.6 ± 5.6 16.2 ± 5.6 16.7 ± 5.6 0.38
CIRS SI, mean ± SD 1.6 ± 0.4 1.7 ± 0.4 1.6 ± 0.4 0.01
CIRS CI, mean ± SD 3.2 ± 1.9 3.4 ± 1.9 3.1 ± 1.9 0.2
Number of drugs, mean ± SD 6.0 ± 2.8 6.2 ± 2.8 5.9 ± 2.8 0.35
Male sex 167 (38.7) 56 (51.9) 111 (34.3) 0.001
ADL, patients with > 2 lost functions, n (%) 258 (59.7) 67 (62.0) 191 (59.0) 0.57
IADL, patients with > 3 lost functions, n (%) 357 (82.6) 93 (86.1) 264 (81.5) 0.27
Stroke, Transient Ischemic Attack (TIA), n (%) 106 (24.5) 29 (26.9) 77 (23.8) 0.52
Psychiatric disorders, n (%) 139 (32.2) 30 (27.8) 109 (33.6) 0.26
Depressive symptoms, n (%) 117 (27.1) 24 (22.2) 95 (29.3) 0.15
Major depressive disorder, n (%) 32 (8.1) 8 (7.4) 24 (7.4) 1
Cardiovascular diseases, n (%) 389 (90.0) 98 (90.7) 291 (89.8) 0.78
Hypertension, n (%) 318 (73.6) 83 (76.9) 237 (73.1) 0.45
Orthostatic hypotension, n (%) 47 (10.9) 4 (3.7) 43 (13.3) 0.006
Coronary artery disease, n (%) 75 (17.4) 22 (20.4) 53 (16.4) 0.34
Congestive heart failure, n (%) 30 (6.9) 11 (10.2) 19 (5.9) 0.13
Atrial fibrillation, n (%) 62 (14.4) 22 (20.4) 40 (12.3) 0.04
Carotid plaques, n (%) 110 (25.5) 24 (22.2) 86 (26.5) 0.37
Types II diabetes mellitus, n (%) 91 (21.1) 29 (26.9) 62 (19.1) 0.09
Thyroid dysfunction, n (%) 45 (10.4) 8 (7.4) 37 (11.4) 0.24
Diuretics, n (%) 154 (35.6) 50 (46.3) 104 (32.1) 0.01
Angiotensin-converting enzyme inhibitors, n (%) 150 (34.7) 36 (33.3) 114 (35.2) 0.73
Angiotensin receptor blockers, n (%) 67 (15.5) 16 (14.8) 51 (15.7) 0.82
Calcium channel blockers, n (%) 77 (17.8) 19 (17.6) 58 (17.9) 0.94
Alpha-blockers, n (%) 57 (13.2) 18 (16.7) 39 (12.0) 0.22
Beta-blockers, n (%) 107 (24.8) 30 (27.8) 77 (23.8) 0.40
Nitrates, n (%) 40 (9.3) 9 (8.3) 31 (9.6) 0.70
Anti-arrhythmics, n (%) 32 (7.4) 12 (11.1) 20 (6.2) 0.09
Digoxin, n (%) 24 (5.6) 5 (4.6) 19 (5.9) 0.63
Antiplatets, n (%) 240 (55.6) 58 (53.7) 182 (56.2) 0.65
Anticoagualants, n (%) 53 (12.3) 15 (13.9) 38 (11.7) 0.55
Insulin, n (%) 28 (6.5) 12 (11.1) 16 (4.9) 0.02
Oral glucose lowering drugs, n (%) 57 (13.2) 16 (14.8) 41 (12.7) 0.57
Levothyroxine, n (%) 26 (61.9) 4 (3.7) 22 (6.8) 0.24
Benzodiazepines, n (%) 92 (21.3) 25 (23.1) 67 (20.7) 0.59
Anticonvulsants, n (%) 30 (6.9) 6 (5.6) 24 (7.4) 0.51
Antipsychotics, n (%) 106 (24.5) 26 (24.1) 80 (24.7) 0.90
Antidepressants, n (%) 146 (33.8) 37 (34.3) 109 (33.6) 0.91
Antiparkinsonians, n (%) 44 (10.2) 7 (6.5) 37 (11.4) 0.14
Non-steroidal anti-inflammatory, n (%) 20 (4.6) 4 (3.7) 16 (4.9) 0.60
Cholinesterase inhibitors, n (%) 62 (13.4) 11 (10.2) 51 (15.7) 0.15
Memantine, n (%) 34 (7.9) 7 (6.5) 27 (8.3) 0.54
QTc: corrected QT; ADL: Acitivities of Daily Living scale; IADL: Instrumental Acitivities of Daily Living scale; MMSE: Mini Mental State Examination; CIRS SI:
Cumulative Illness Rating Scale Severity Index; CIRS CI: Cumulative Illness Rating Scale Comorbidity Index.
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Table 2
Variables associated with death and recurrence of syncope or unexplained fall: univariate analysis.
Dead (n=83) Alive (n=272) p Recurrence of syncope/unexplained fall
(n= 108)
Not recurrence of syncope/unexplained
fall(n=247)
p
Age, years, mean ± SD 84.1 ± 5.9 82.5 ± 6.3 0.03 82.8 ± 6.0 82.9 ± 6.3 0.90
Heart rate, mean ± SD 79.7 ± 16.6 73.2 ± 14.4 0.001 73.7 ± 14.2 75.1 ± 15.5 0.45
ADL score, mean ± SD 3.5 ± 2.1 2.9 ± 2.0 0.01 3.1 ± 2.0 3.0 ± 2.1 0.58
Number of drugs, mean ± SD 6.0 ± 2.7 6.0 ± 2.9 0.97 6.5 ± 2.9 5.8 ± 2.8 0.03
CIRS SI, mean ± SD 1.7 ± 0.3 1.6 ± 0.4 0.006 1.57 ± 0.4 1.6 ± 0.4 0.47
CIRS CI, mean ± SD 3.6 ± 1.9 3.1 ± 1.9 0.06 3.2 ± 1.9 3.3 ± 1.9 0.77
Sex 0.0001 0.10
Male, n (%) 34 (41.0) 183 (67.3) 73 (67.6) 144 (58.3)
Female, n (%) 49 (59.0) 89 (32.7) 35 (32.4) 103 (41.7)












Patients with >2 lost functions, n
(%)
21 (25.3) 58 (21.3) 15 (13.9) 87 (35.2)
Patients with <2 lost functions, n
(%)
62 (74.7) 214 (78.7) 93 (86.1) 160 (64.8)
IADL 0.061 0.56
Patients with >3 lost functions, n
(%)
7 (8.4) 72 (26.5) 9 (8.3) 93 (37.7)
Patients with <3 lost functions, n
(%)
76 (91.6) 200 (73.5) 99 (91.7) 154 (62.3)
Psychiatric disorders 0.02 0.80
Present, n (%) 18 (21.7) 97 (35.7) 36 (33.3) 79 (32.0)
Absent, n (%) 65 (78.3) 175 (64.3) 72 (66.7) 168 (68.0)
Depressive symptoms 0.65 0.11
Present, n (%) 6 (7.2) 24 (8.8) 13 (12.0) 17 (6.9)
Absent, n (%) 77 (92.8) 248 (91.2) 95 (88.0) 230 (93.1)
Congestive heart failure 0.02 0.40
Present, n (%) 11 (13.3) 15 (5.5) 6 (5.6) 20 (8.1)
Absent, n (%) 72 (86.7) 257 (94.5) 102 (94.4) 227 (91.9)
Atrial fibrillation 0.003 0.46
Present, n (%) 20 (24.1) 30 (11.0) 13 (12.0) 37 (15.0)
Absent, n (%) 63 (75.9) 242 (89.0) 95 (88.0) 210 (85.0)
Carotid plaques 0.49 0.04
Present, n (%) 18 (21.7) 69 (25.4) 34 (31.5) 53 (21.5)
Absent, n (%) 65 (78.3) 203 (74.6) 74 (68.5) 194 (78.5)
Calcium channel blockers 0.05 0.05
Present, n (%) 21 (25.3) 43 (15.8) 13 (12.0) 51 (20.6)
Absent, n (%) 62 (74.7) 229 (84.2) 95 (88.0) 196 (79.4)
Antiplatelets
Present, n (%) 44 (53.0) 154 (56.6) 70 (64.8) 128 (51.8)
Absent, n (%) 39 (47.0) 118 (43.4) 0.56 38 (35.2) 119 (48.2) 0.02
Anticoagulants 0.02 0.28
Present, n (%) 16 (19.3) 27 (9.9) 10 (9.3) 33 (13.4)
Absent, n (%) 67 (80.7) 245 (90.1) 98 (90.7) 214 (86.6)
Antipsychotics 0.57 0.01
Present, n (%) 23 (27.7) 67 (24.6) 37 (34.3) 53 (21.5)
Absent, n (%) 60 (72.3) 205 (75.4) 71 (65.7) 194 (78.5)
Cholinesterase inhibitors 0.06 0.03
Present, n (%) 7 (8.4) 46 (16.9) 23 (21.3) 30 (12.1)
Absent, n (%) 76 (91.6) 226 (83.1) 85 (78.7) 217 (87.9)
ADL: Acitivities of Daily Living scale; IADL: Instrumental Acitivities of Daily Living scale; CIRS SI: Cumulative Illness Rating Scale Severity Index; CIRS CI: Cumulative
Illness Rating Scale Comorbidity Index; QTc: corrected QT.
Table 3
Variables significantly associated with one-year mortality (Model 1and Model 2).
Model 1 Model 2
ß SE(ß) OR 95% IC p ß SE(ß) OR 95% IC p
Male sex 1.22 0.28 3.38 1.94–5.89 0.000 1.25 0.28 3.49 2.01–6.07 0.000
Atrial fibrillation 0.68 0.35 1.98 1.15–4.13 0.05 – – – – –
Calcium channel blockers 0.78 0.33 2.18 1.00–3.89 0.02 0.82 0.32 2.26 1.20–4.27 0.01
Prolonged QTc 0.59 0.30 1.80 1.01–3.20 0.05 – – – – –
Age 0.06 0.06 1.06 1.02–1.11 0.001 0.07 0.02 1.07 1.02–1.12 0.004
Prolonged QTc with concomitant AF – – – – – 1.53 0.52 4.62 1.68–2.75 0.003
QTc: corrected QT; AF: Atrial Fibrillation.
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not defined. It has been suggested that QT interval prolongation might
be at least in part due to diuretic-induced hypomagnesemia, but there
are no definite data at this regard [22,29]. Certainly both conditions are
very frequent in older individuals, that are particularly vulnerable to
the depleting effects of diuretics.
In this sample of older patients with dementia, antipsychotic drugs,
although widely used, were not associated with prolonged QTc interval.
Results did not differ analyzing separately typical and atypical anti-
psychotic drugs (data not shown). Although there is no doubt that an-
tipsychotic drugs have the potential to cause arrhythmias, the ion
channel effects of most drugs are relatively weak [30–33], and it is
possible that these medications do not intrinsically prolong the QTc
interval [34]. Moreover, QTc by itself is a weak predictor of torsade de
pointes and sudden cardiac death [35], and there is no clear consensus
on the correct approach for managing QT-prolonging risk with anti-
psychotics [30]. However, in the present study we were not able to
identify sudden death events, thereby reducing clinical implications of
present findings.
In our analysis prolonged QTc, and QTc prolongation with con-
comitant AF, were associated with a two-fold and more than four-fold
increased risk of all-cause mortality, respectively. Our findings add on
and reinforce previous studies which demonstrated that long QTc is a
risk factor for all-cause mortality [23,28,34]. Several studies confirmed
this association among adult patients in different clinical settings, with
risk of all-cause mortality approximately triplicated, as well in older
patients [36–40]. Pickham et al. [36] reported a risk of all-cause mor-
tality approximately triplicated in a cohort of intensive care unit adult
patients. Nakanishi et al. [37] demonstrated that individuals with
prolonged QT have a two-fold increased risk of death in a sample of
3543 elderly Japanese patients. In the Rotterdam study (3484 patients,
mean age 69.1, SD 8.1 years) QT prolongation was associated with a
two-fold increased risk of mortality, with a significant increased risk of
sudden cardiac death only in participants with a consistently prolonged
QT defined as presence of a prolonged QT on two consecutive elec-
trocardiograms [39]. However, some of these studies [37,40] excluded
patients who were taking medications potentially associated with in-
creased risk of prolonged QT, and no study used a comprehensive
multidimensional evaluation; present findings, demonstrating a sig-
nificant association of prolonged QTc with mortality on top of a stan-
dardized cardiologic protocol and a multidimensional geriatric assess-
ment, confirm the robustness and strength to this association.
In our study, AF was found to be an important risk factor for death
in both models, and QTc prolongation with concomitant AF was asso-
ciated with a more than four-fold increased risk of mortality.
Concomitant prolonged QTc interval and AF might be expression of an
increased severity of structural cardiac disease, thereby underlying in-
creased individual vulnerability and risk of death. Moreover, the pre-
sence of both these conditions has been reported to be associated with a
five-fold enhanced risk of heart failure [41]. Unfortunately, we were
not able to ascertain the cause of death in study patients; further pro-
spective studies should address this causal association in older poly-
morbid patients.
Calcium channel blockers were the only drug class associated with a
statistically significant increased risk of mortality in our study, which
was more than doubled in patients receiving these drugs (OR 2.18 and
OR 2.26 in model 1 and model 2, respectively). In literature there is
scant evidence about this issue and, moreover, in our study calcium
channel blockers were considered all together, without differentiating
between dihydropyridinic and non-dihydropyridinic ones. Data are
intriguing but despite the observational prospective design, the com-
prehensive multidimensional assessment and the statistical analysis, we
can't definitively exclude a chance result.
Finally, prolonged QTc interval was not significantly associated
with recurrent events, which were significantly more frequent in pa-
tients treated with antiplatelet drugs, cholinesterase inhibitors and
antipsychotics. Use of cholinesterase inhibitors and antipsychotics
might suggest a more advanced stage of dementia, with behavioral
symptoms, thereby portending an increased risk of recurrent events,
mainly falls. It is more difficult to find explanations for the observed
association of antiplatelet drugs with recurrent events, which remained
significant after correcting for cardiovascular variables such as history
of stroke, TIA or ischemic heart disease. Use of antiplatelet drugs might
be a surrogate of perceived increased risk of cardiovascular events or of
vascular dementia, this latter being associated with an increased risk of
falls. However, a causal relation seems unlikely.
In our view, the present prospective study has several strengths,
including the multicenter enrollment, the standardized cardiologic
evaluation and the comprehensive multidimensional geriatric assess-
ment. Therefore, patients enrolled may be considered representative of
the vast group of real world older in- and out-patients with dementia
admitted for suspected syncope. For the same reasons, these findings
should not be generalized to “healthier” elderly subjects without cog-
nitive impairment and with better clinical and functional status. Some
limitations should be considered too. Firstly, we were not able to as-
certain specific cause of death in all patients and, therefore, we could
not discriminate how much sudden cardiac death contributed to overall
mortality and whether prolonged QTc was associated also with in-
creased risk of sudden death, thus potentially reducing clinical im-
plications of the present findings. However, the principal aim of this
study was to evaluate whether QTc prolongation was significantly as-
sociated with increased overall mortality (or recurrent events), despite
the multiple concurrent potential causes of death and falls among these
older and vulnerable patients. Secondly, as discussed above, we could
not evaluate potential modifications of QTc length during follow up,
thereby making impossible to ascertain whether further prolonging of
QTc length occurred in patients with adverse outcomes. Therefore,
despite the well documented potential causal link and the independent
association observed, whether QTc interval prolongation is a risk factor
for, rather than a marker of, increased mortality risk in these patients
remains a matter of discussion. Although other formulas are available
for QTc measurement, the Bazett's formula (which does not correct for
gender and might under- and overestimate QTc at very low and very
high heart rate) is currently one of the most widely used in clinical
practice. By the way, in our sample of patients medium heart rate was
74.4, and only 78 patients (18%) had heart rate lower than 60 bpm or
higher than 100 bpm. Indeed, results did not significantly change when
the analysis was performed using the method proposed by Sagie et al.
[42]. Moreover, although the severity of QT prolongation has clinical
relevance, we deliberately did not consider the association between
absolute QTc intervals and prolonged QTc, since in clinical practice
physicians usually rely on prolonged QTc rather than on its absolute
value.
Despite these limitations, our findings have potential clinical im-
plications. Dementia and cognitive impairment are common chronic
conditions affecting older individuals and, in these patients, falls and
suspected syncope are frequent cause of admission to hospital [43–45].
Most of these vulnerable patients usually are treated with one or more
psychoactive medications and other concomitant drug therapy poten-
tially associated with QTc prolonging effect [30,46]. Our findings
suggest that diuretics, rather than antipsychotics, are closely associated
with prolonged QTc in these patients. Therefore, present findings sug-
gest the need of a careful and inclusive review of all drug therapies
potentially implicated with prolonged QTc and of regular ECG mon-
itoring in these older patients receiving polypharmacy.
5. Conclusions
In this cohort of older patients with dementia and suspected syn-
cope, we demonstrated a high prevalence of prolonged QTc, that was
associated with male gender and diuretic use. QTc prolongation, by
itself and with concomitant AF, was associated with a two-fold and
four-fold increased risk of mortality, respectively.
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